Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 11/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9369675 | 0.89 | PTGER3 (0.47) | PTGER4PTGER3PTGER2BCHEPTGER1 | |
| SCHEMBL28877513 | 0.87 | CCNB2 (0.53) | PTGER4PTGER3PTGER2BCHEPTGER1 | |
| SCHEMBL17772584 | 0.86 | PTGER3 (0.45) | PTGER4PTGER3PTGER2BCHEPTGER1 | |
| SCHEMBL25760584 | 0.85 | PTGER4 (0.49) | PTGER4PTGER3PTGER2BCHEPTGER1 | |
| SCHEMBL2574855 | 0.83 | PTGER4 (0.55) | PTGER4PTGER3PTGER2PTGER1CCNB2 | |
| SCHEMBL1539550 | 0.82 | ALDH1A1 (0.43) | PTGER4PTGER3PTGER2CDK4CCND1 | |
| SCHEMBL27754527 | 0.82 | CA1 (0.44) | GAA | |
| SCHEMBL1050281 | 0.81 | CCNB2 (0.59) | PTGER4PTGER3PTGER2BCHEPTGER1 | |
| SCHEMBL16180183 | 0.80 | LIPE (0.55) | PTGER4PTGER3PTGER2PTGER1CCNB2 | |
| SCHEMBL1125006 | 0.80 | KDM4E (0.60) | PTGER4PTGER3PTGER2BCHECCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PTGER4 2147/4885PTGER3 4074/4885PTGER2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.